//19 Sep 2011
Minimum standards of animal welfare and recommended best practices for everyone involved in transporting animals in New Zealand have been outlined in a new code of welfare issued by Agriculture Minister David Carter.
The Animal Welfare (Transport within New Zealand) Code of Welfare 2011, developed by the National Animal Welfare Advisory Committee (NAWAC), encourages all those responsible for animals during transport to adopt the highest standards of husbandry, care and handling.
NAWAC Deputy Chair Hilton Collier says transport can be a time of great stress for animals and it is important that it is done well.
“The purpose of this new code of welfare is to encourage everyone involved to minimise the stress placed on animals by adopting the highest standards before and during transport”.
“The code covers all animals and all forms of transport within New Zealand – air, land and sea. Minimum standards cover off important areas like stockmanship; planning; equipment design and maintenance; preparing and selecting animals for transport; loading and unloading; and the provision of food, water and rest”.
Collier adds that specific requirements for transport in emergencies and emergency humane destruction are also included.
The code was drafted and reviewed by representatives of companies and organisations involved in the commercial transport of animals by road and sea, farmers, veterinarians, animal advocacy groups and environmental agencies
Showing posts with label new. Show all posts
Showing posts with label new. Show all posts
19 September 2011
14 September 2011
New prestarter feed reducing stress in piglets
//14 Sep 2011
French animal nutrition company CCPA launches its global approach around demedicalisation at SPACE, in Rennes, France. Core product in this approach is the prestarter feed Ax’Écla.
The prestarter feed includes selected ingredients with antioxidant and anti-inflammatory properties and has been designed for piglets having high levels of oxidative stress.
Oxidative stress, often occurring during weaning, induces immunodepression, in which defense capabilities of the body are exceeded by the production of ‘free radicals’. These unstable molecules coming from the redox process enhance cell damage and induce a decrease of animal health.
Inflammatory stress is often induced by this process, leading to growth retardation growth. Generally, this type of stress disappears rapidly five to six days after weaning, but in sick animals, it continues.
Disease susceptibility
The novel product reduces piglet susceptibility to diseases by correcting oxidative stress around weaning and stimulating antioxidant defense mechanisms.
The formulation lowers the indigestible fraction of proteins. In poor sanitary conditions, a high protein level in the piglet feed leads to an increase of inflammation. The use of soluble and fermentable specific fibres contributes to maintain beneficial flora in the gut and improves nutrient digestibility.
As a consequence, animal performance goes up and medication costs go down. The product has already been used by some customers, especially in difficult sanitary situations where conventional approach with antibiotics was ineffective.
Diagnosis tool
CCPA has already been around in the business of stress in piglets for quite some years. The company received an Innov’Space award in 2009 for its diagnosis tool Axiscale, to be used for evaluation of the level of stress experienced by piglets. Using blood tests at weaning, levels of oxidative stress can be determined, on a scale from 0 to 20. In the global field sample data, 50% of piglets presented a note of oxidative stress above 10, considered a medium to high level.
SPACE is held in Rennes’ Parc Expo, from 13-16 September 2011.
CCPA can be found in Hall 5, Stand B41
Related websites:
• SPACE
• CCPA
French animal nutrition company CCPA launches its global approach around demedicalisation at SPACE, in Rennes, France. Core product in this approach is the prestarter feed Ax’Écla.
The prestarter feed includes selected ingredients with antioxidant and anti-inflammatory properties and has been designed for piglets having high levels of oxidative stress.
Oxidative stress, often occurring during weaning, induces immunodepression, in which defense capabilities of the body are exceeded by the production of ‘free radicals’. These unstable molecules coming from the redox process enhance cell damage and induce a decrease of animal health.
Inflammatory stress is often induced by this process, leading to growth retardation growth. Generally, this type of stress disappears rapidly five to six days after weaning, but in sick animals, it continues.
Disease susceptibility
The novel product reduces piglet susceptibility to diseases by correcting oxidative stress around weaning and stimulating antioxidant defense mechanisms.
The formulation lowers the indigestible fraction of proteins. In poor sanitary conditions, a high protein level in the piglet feed leads to an increase of inflammation. The use of soluble and fermentable specific fibres contributes to maintain beneficial flora in the gut and improves nutrient digestibility.
As a consequence, animal performance goes up and medication costs go down. The product has already been used by some customers, especially in difficult sanitary situations where conventional approach with antibiotics was ineffective.
Diagnosis tool
CCPA has already been around in the business of stress in piglets for quite some years. The company received an Innov’Space award in 2009 for its diagnosis tool Axiscale, to be used for evaluation of the level of stress experienced by piglets. Using blood tests at weaning, levels of oxidative stress can be determined, on a scale from 0 to 20. In the global field sample data, 50% of piglets presented a note of oxidative stress above 10, considered a medium to high level.
SPACE is held in Rennes’ Parc Expo, from 13-16 September 2011.
CCPA can be found in Hall 5, Stand B41
Related websites:
• SPACE
• CCPA
31 July 2011
Merck’s new coccidiosis vaccine approved for US poultry market
//22 Jul 2011
Merck Animal Health has obtained regulatory approval from the US Department of Agriculture for Coccivac-D2 — a new-generation version of a coccidiosis vaccine to replace Coccivac-D.
“Coccivac-D2 builds on the field-proven performance and dependability of Coccivac-D, but its spectrum is even more in step with the Eimeria populations found in today’s broiler-breeder and layer operations,” said Charlie Broussard, DVM, director of US poultry technical services.
He explained that Coccivac-D2 has a more focused antigen profile of the six major species of chicken coccidia (E. tenella, E. mivati, E. acervulina, E. maxima, E. brunetti and E. necatrix.) “We eliminated E. hagani and E. praecox, two of the least important pathogenic Eimeria species of the chicken,” Broussard added.
As with all Coccivac vaccines, Coccivac-D2 provides a balanced, controlled dose of live Eimeria oocysts to stimulate the bird’s natural immunity against this costly and highly prevalent disease. Coccivac-D2 is currently available in 5,000-dose and 1,000-dose vials.
The development of Coccivac-D2 is the result of Merck Animal Health’s ongoing commitment to quality control. As part of this process, all master seeds used to produce the vaccinal oocysts in Coccivac-D2 were tested for purity, quality and re-qualified by USDA. This new product will also help streamline production and result in a more efficient manufacturing process for Merck Animal Health coccidiosis vaccines for poultry.
Source: Merck Animal Health
Merck Animal Health has obtained regulatory approval from the US Department of Agriculture for Coccivac-D2 — a new-generation version of a coccidiosis vaccine to replace Coccivac-D.
“Coccivac-D2 builds on the field-proven performance and dependability of Coccivac-D, but its spectrum is even more in step with the Eimeria populations found in today’s broiler-breeder and layer operations,” said Charlie Broussard, DVM, director of US poultry technical services.
He explained that Coccivac-D2 has a more focused antigen profile of the six major species of chicken coccidia (E. tenella, E. mivati, E. acervulina, E. maxima, E. brunetti and E. necatrix.) “We eliminated E. hagani and E. praecox, two of the least important pathogenic Eimeria species of the chicken,” Broussard added.
As with all Coccivac vaccines, Coccivac-D2 provides a balanced, controlled dose of live Eimeria oocysts to stimulate the bird’s natural immunity against this costly and highly prevalent disease. Coccivac-D2 is currently available in 5,000-dose and 1,000-dose vials.
The development of Coccivac-D2 is the result of Merck Animal Health’s ongoing commitment to quality control. As part of this process, all master seeds used to produce the vaccinal oocysts in Coccivac-D2 were tested for purity, quality and re-qualified by USDA. This new product will also help streamline production and result in a more efficient manufacturing process for Merck Animal Health coccidiosis vaccines for poultry.
Source: Merck Animal Health
20 July 2011
New production tower at Perfect Companion, Thailand
//19 Jul 2011
Pet food manufacturer Perfect Companion in Thailand is in the process of building a new production plant to meet growing consumer demand. SCE supplied silos for storage of ingredients.
The concept of producing pet foods nowadays is almost similar to producing human food. Pet owners carefully select the feed for their animals and want to be sure this is safe, clean and healthy.
In Thailand the Perfect companion Group is well aware of this trend and adapted their production facility to the changing quality demands.
Continuous investments keep their product facility in line with international standards and are one of the key success factors in the very competitive pet food industry.
Perfect Companion has selected SCE silo systems for their new production tower in Bangkok.
In cooperation with US engineering company Ibberson Belgium based silo construction and engineering company SCE supplied a silo unit with 41 smooth wall cell and chutes which an integral part of the production tower.
Perfect Companion Group operates as a subsidiary of Charoen Pokphand Group and develops, produces, and sells food products for diverse range of companion animals in Thailand and internationally.
In addition, it provides professional services, such as products concept development, research and testing, packaging development and design, product manufacturing, brand development, promotional marketing, and product distribution services, as well as services for original equipment manufacturers.
The company was founded in 2001 and is based in Bangkok, Thailand with additional offices in Kuala Lumpur, Malaysia; and Vietnam.
Pet food manufacturer Perfect Companion in Thailand is in the process of building a new production plant to meet growing consumer demand. SCE supplied silos for storage of ingredients.
The concept of producing pet foods nowadays is almost similar to producing human food. Pet owners carefully select the feed for their animals and want to be sure this is safe, clean and healthy.
In Thailand the Perfect companion Group is well aware of this trend and adapted their production facility to the changing quality demands.
Continuous investments keep their product facility in line with international standards and are one of the key success factors in the very competitive pet food industry.
Perfect Companion has selected SCE silo systems for their new production tower in Bangkok.
In cooperation with US engineering company Ibberson Belgium based silo construction and engineering company SCE supplied a silo unit with 41 smooth wall cell and chutes which an integral part of the production tower.
Perfect Companion Group operates as a subsidiary of Charoen Pokphand Group and develops, produces, and sells food products for diverse range of companion animals in Thailand and internationally.
In addition, it provides professional services, such as products concept development, research and testing, packaging development and design, product manufacturing, brand development, promotional marketing, and product distribution services, as well as services for original equipment manufacturers.
The company was founded in 2001 and is based in Bangkok, Thailand with additional offices in Kuala Lumpur, Malaysia; and Vietnam.
03 July 2011
Merck: New name for animal health division
//30 Jun 2011
Merck’s animal health division, formerly known as Intervet/Schering-Plough Animal Health, announced that effective immediately it will begin using the new name, Merck Animal Health. It will be known as MSD Animal Health outside the United States and Canada.
“The name change reflects Merck's commitment to animal health and its complementary role to the overall business," said Raul Kohan, President of Merck Animal Health. "We are unwavering in our commitment to veterinarians, producers, pet owners and society as a whole. We aim to generate additional value and sustained growth by continuing to provide integrated solutions with innovative animal health products and services to meet the evolving needs of our customers."
Mr. Kohan continued, "With the scientific and business backing of Merck, Merck Animal Health possesses the necessary mix of resources to enhance our position as an industry leader."
Merck Animal Health is a global leader in the research, development, manufacturing and sale of veterinary medicines and vaccines, with a strong presence in biologics and pharmaceuticals. The division generated global sales of $2.9 billion in 2010.
Merck values the diversification that Merck Animal Health brings to its portfolio, and sees growth opportunities in the business that can be leveraged across both animal and human health. The company intends to capitalize on Merck Animal Health's broad and innovative portfolio going forward, and to develop the unit into a best-in-class global animal health leader.
The name change follows the joint announcement on March 22, 2011 by
Merck and sanofi-aventis that ended plans to form a new animal health joint venture. Both companies mutually decided to discontinue their agreement primarily because of the increasing complexity of implementing the proposed transaction.
Merck’s animal health division, formerly known as Intervet/Schering-Plough Animal Health, announced that effective immediately it will begin using the new name, Merck Animal Health. It will be known as MSD Animal Health outside the United States and Canada.
“The name change reflects Merck's commitment to animal health and its complementary role to the overall business," said Raul Kohan, President of Merck Animal Health. "We are unwavering in our commitment to veterinarians, producers, pet owners and society as a whole. We aim to generate additional value and sustained growth by continuing to provide integrated solutions with innovative animal health products and services to meet the evolving needs of our customers."
Mr. Kohan continued, "With the scientific and business backing of Merck, Merck Animal Health possesses the necessary mix of resources to enhance our position as an industry leader."
Merck Animal Health is a global leader in the research, development, manufacturing and sale of veterinary medicines and vaccines, with a strong presence in biologics and pharmaceuticals. The division generated global sales of $2.9 billion in 2010.
Merck values the diversification that Merck Animal Health brings to its portfolio, and sees growth opportunities in the business that can be leveraged across both animal and human health. The company intends to capitalize on Merck Animal Health's broad and innovative portfolio going forward, and to develop the unit into a best-in-class global animal health leader.
The name change follows the joint announcement on March 22, 2011 by
Merck and sanofi-aventis that ended plans to form a new animal health joint venture. Both companies mutually decided to discontinue their agreement primarily because of the increasing complexity of implementing the proposed transaction.
30 June 2011
Aviagen opens new veterinary diagnostic and research laboratory
//29 Jun 2011
Aviagen’s commitment to meet increasingly demanding domestic and international poultry health requirements continued to advance as it opens a new diagnostic and research laboratory in Elkmont, Alabama, USA.
The new laboratory provides expanded and dedicated areas for an array of laboratory work including bacteriology, serology, molecular diagnostics, genomics research, and pathological exams.
The multimillion-dollar facility was designed to meet biosafety level II (BSL-II) standards and rigorous employee safety criteria. The lab will serve the needs of all Aviagen breeding-production facilities in the US.
With office space for five veterinarians, a microbiologist, and an information management system administrator, Aviagen’s new laboratory will initially be staffed by 20 employees.
Authorized laboratory
This facility is an authorized National Poultry Improvement Plan (NPIP) Laboratory and reflects the company’s dedication to ensuring the health status of its breeding stock and products, and its support of the broiler industry’s efforts to promote food safety.
“The new laboratory will help Aviagen meet the growing needs of its breeding program and production units,” said Dr. Gregorio Rosales, Vice President of Veterinary Services.
“This laboratory is an essential component that will allow us to maintain a [leading] role in the future and safeguard the supply of breeding stock to our customers in the US and over 45 countries around the world.”
Aviagen designed the lab with a commitment to maintaining strict biosecurity throughout. Access to laboratory areas is restricted to lab personnel only.
Bacteriology and pathological exam rooms have separate ventilation systems to prevent any cross-contamination. A drive-through window allows company personnel to drop off samples for testing without entering the facility.
To see more you can take a virtual tour of the lab
Aviagen’s commitment to meet increasingly demanding domestic and international poultry health requirements continued to advance as it opens a new diagnostic and research laboratory in Elkmont, Alabama, USA.
The new laboratory provides expanded and dedicated areas for an array of laboratory work including bacteriology, serology, molecular diagnostics, genomics research, and pathological exams.
The multimillion-dollar facility was designed to meet biosafety level II (BSL-II) standards and rigorous employee safety criteria. The lab will serve the needs of all Aviagen breeding-production facilities in the US.
With office space for five veterinarians, a microbiologist, and an information management system administrator, Aviagen’s new laboratory will initially be staffed by 20 employees.
Authorized laboratory
This facility is an authorized National Poultry Improvement Plan (NPIP) Laboratory and reflects the company’s dedication to ensuring the health status of its breeding stock and products, and its support of the broiler industry’s efforts to promote food safety.
“The new laboratory will help Aviagen meet the growing needs of its breeding program and production units,” said Dr. Gregorio Rosales, Vice President of Veterinary Services.
“This laboratory is an essential component that will allow us to maintain a [leading] role in the future and safeguard the supply of breeding stock to our customers in the US and over 45 countries around the world.”
Aviagen designed the lab with a commitment to maintaining strict biosecurity throughout. Access to laboratory areas is restricted to lab personnel only.
Bacteriology and pathological exam rooms have separate ventilation systems to prevent any cross-contamination. A drive-through window allows company personnel to drop off samples for testing without entering the facility.
To see more you can take a virtual tour of the lab
Merck Animal Health new name for Intervet Schering-Plough
//30 Jun 2011
Merck’s animal health division, formerly known as Intervet/Schering-Plough Animal Health, announced that it will begin using the new name, Merck Animal Health. It will be known as MSD Animal Health outside the United States and Canada.
“The name change reflects Merck's commitment to animal health and its complementary role to the overall business," said Raul Kohan, President of Merck Animal Health. "We are unwavering in our commitment to veterinarians, producers, and society as a whole. We aim to generate additional value and sustained growth by continuing to provide integrated solutions with innovative animal health products and services to meet the evolving needs of our customers."
Mr. Kohan continued, "With the scientific and business backing of Merck, Merck Animal Health possesses the necessary mix of resources to enhance our position as a world player in the industry."
Merck Animal Health is a global leading company in the research, development, manufacturing and sale of veterinary medicines and vaccines, with a strong presence in biologics and pharmaceuticals. The division generated global sales of $2.9 billion in 2010.
Merck values the diversification that Merck Animal Health brings to its portfolio, and sees growth opportunities in the business that can be leveraged across both animal and human health. The company intends to capitalize on Merck Animal Health's broad and innovative portfolio going forward, and to develop the unit into a best-in-class global animal health leader.
The name change follows the joint announcement on March 22, 2011 by Merck and sanofi-aventis that ended plans to form a new animal health joint venture. Both companies mutually decided to discontinue their agreement primarily because of the increasing complexity of implementing the proposed transaction.
Related website: Merck Animal Health
Merck’s animal health division, formerly known as Intervet/Schering-Plough Animal Health, announced that it will begin using the new name, Merck Animal Health. It will be known as MSD Animal Health outside the United States and Canada.
“The name change reflects Merck's commitment to animal health and its complementary role to the overall business," said Raul Kohan, President of Merck Animal Health. "We are unwavering in our commitment to veterinarians, producers, and society as a whole. We aim to generate additional value and sustained growth by continuing to provide integrated solutions with innovative animal health products and services to meet the evolving needs of our customers."
Mr. Kohan continued, "With the scientific and business backing of Merck, Merck Animal Health possesses the necessary mix of resources to enhance our position as a world player in the industry."
Merck Animal Health is a global leading company in the research, development, manufacturing and sale of veterinary medicines and vaccines, with a strong presence in biologics and pharmaceuticals. The division generated global sales of $2.9 billion in 2010.
Merck values the diversification that Merck Animal Health brings to its portfolio, and sees growth opportunities in the business that can be leveraged across both animal and human health. The company intends to capitalize on Merck Animal Health's broad and innovative portfolio going forward, and to develop the unit into a best-in-class global animal health leader.
The name change follows the joint announcement on March 22, 2011 by Merck and sanofi-aventis that ended plans to form a new animal health joint venture. Both companies mutually decided to discontinue their agreement primarily because of the increasing complexity of implementing the proposed transaction.
Related website: Merck Animal Health
28 June 2011
New salmonella superbug passing from pigs to humans
//28 Jun 2011
The Soil Association is calling on the UK Government to take immediate action to limit the spread of a deadly new type of salmonella which is passing from pigs to humans. Known as ‘monophasic salmonella typhimurium’.
The new superbug has enhanced ability to cause infections and 'a particularly high attack rate in children and old people', leading to 'an unusually high rate of hospitalisation'. It is also highly resistant to antibiotics, limiting treatment options.
Several different strains have already emerged and caused numerous infections in humans and at least one death. Professor John Trelfall from the Health Protection Agency has acknowledged that it appears ‘to be associated with pigs and pig products’. German scientists have found clear evidence it is being transmitted from pigs to humans ‘along the food chain’, and called for interventions at a farm level to prevent human infection.
The Soil Association wants a panel of experts to undertake an urgent review of the mounting evidence that specific action is needed to address the serious threat posed by the new type of salmonella, and evidence that all Salmonella can spread directly from pigs to people, as well as via food. It also wants Caroline Spelman, Secretary of State for the Environment, to intervene and stop any new intensive pig farms being built near residential areas at least until the panel has made recommendations.
Planners in Derbyshire will shortly decide whether or not to approve one of the largest ever pig farms in the UK for the company Midland Pig Producers on the outskirts of the village of Foston, which would house 25,000 pigs. The Soil Association is staging an open meeting with Pig Business today for local residents concerned about the proposed development.
Exact statistics on the number of cases in the UK are not available, but the Government’s main advisory committee on antibiotic resistance in animals has warned that it ‘appeared currently to be the most predominant type of salmonella in Europe’. The European Food Safety Authority has described its incidence as ‘epidemic’. The available evidence strongly suggests that it is increasing in pigs and humans in the UK. There have also been cases in British cattle.
Resistant to antibiotics
Most monophasic salmonella from pigs are multiresistant to at least four families of antibiotics, but the long-feared development of resistance to modern cephalosporin antibiotics in salmonella has already been found as well on at least one British pig farm. The European Food Safety Authority has warned that resistance to these antibiotics could lead to treatment failures. They also warned that even the routine use of antibiotics such as tetracyclines, the most widely used antibiotics in pig feed, not only promotes resistance but also increases the spread and persistence in pigs of these resistant strains.
Flies and cockroaches are known to carry salmonella and other pathogens found on pigs, and American scientists have said that because these insects can move freely between animal waste on farms and nearby houses there is ‘increasing concern in the medical and public-health community about insect pests directly associated with the spread of bacterial pathogens and antibiotic-resistant microorganisms with animal production systems to residential settings’. This is particularly significant because Dr Rob Davies, from the Veterinary Laboratories Agency, believes that monophasic Salmonella typhimurium may have ‘the ability to be shed in large numbers in faeces compared with other strains’. Flies were a particular problem on one of Midland Pig Producers' other pig farms when journalists visited it last year.
Evolved strains
According to Dr Davies, monophasic salmonella typhimurium is one of several salmonella strains to have evolved in pigs. Furthermore, another very recently published government study found that 28% of British pigs tested positive for salmonella. 92% of these showed resistance to antibiotics with 67% being multiresistant. A British government survey in 2002 found that one in every twelve sausages (8.6%) were contaminated with salmonella.
Research has shown that pigs raised indoors excrete higher levels of salmonella in their manure than do outdoor-raised pigs, both organic and non-organic. Many scientific studies also show that salmonella in pigs increases with herd size.
Source and for more information: Soil Association
The Soil Association is calling on the UK Government to take immediate action to limit the spread of a deadly new type of salmonella which is passing from pigs to humans. Known as ‘monophasic salmonella typhimurium’.
The new superbug has enhanced ability to cause infections and 'a particularly high attack rate in children and old people', leading to 'an unusually high rate of hospitalisation'. It is also highly resistant to antibiotics, limiting treatment options.
Several different strains have already emerged and caused numerous infections in humans and at least one death. Professor John Trelfall from the Health Protection Agency has acknowledged that it appears ‘to be associated with pigs and pig products’. German scientists have found clear evidence it is being transmitted from pigs to humans ‘along the food chain’, and called for interventions at a farm level to prevent human infection.
The Soil Association wants a panel of experts to undertake an urgent review of the mounting evidence that specific action is needed to address the serious threat posed by the new type of salmonella, and evidence that all Salmonella can spread directly from pigs to people, as well as via food. It also wants Caroline Spelman, Secretary of State for the Environment, to intervene and stop any new intensive pig farms being built near residential areas at least until the panel has made recommendations.
Planners in Derbyshire will shortly decide whether or not to approve one of the largest ever pig farms in the UK for the company Midland Pig Producers on the outskirts of the village of Foston, which would house 25,000 pigs. The Soil Association is staging an open meeting with Pig Business today for local residents concerned about the proposed development.
Exact statistics on the number of cases in the UK are not available, but the Government’s main advisory committee on antibiotic resistance in animals has warned that it ‘appeared currently to be the most predominant type of salmonella in Europe’. The European Food Safety Authority has described its incidence as ‘epidemic’. The available evidence strongly suggests that it is increasing in pigs and humans in the UK. There have also been cases in British cattle.
Resistant to antibiotics
Most monophasic salmonella from pigs are multiresistant to at least four families of antibiotics, but the long-feared development of resistance to modern cephalosporin antibiotics in salmonella has already been found as well on at least one British pig farm. The European Food Safety Authority has warned that resistance to these antibiotics could lead to treatment failures. They also warned that even the routine use of antibiotics such as tetracyclines, the most widely used antibiotics in pig feed, not only promotes resistance but also increases the spread and persistence in pigs of these resistant strains.
Flies and cockroaches are known to carry salmonella and other pathogens found on pigs, and American scientists have said that because these insects can move freely between animal waste on farms and nearby houses there is ‘increasing concern in the medical and public-health community about insect pests directly associated with the spread of bacterial pathogens and antibiotic-resistant microorganisms with animal production systems to residential settings’. This is particularly significant because Dr Rob Davies, from the Veterinary Laboratories Agency, believes that monophasic Salmonella typhimurium may have ‘the ability to be shed in large numbers in faeces compared with other strains’. Flies were a particular problem on one of Midland Pig Producers' other pig farms when journalists visited it last year.
Evolved strains
According to Dr Davies, monophasic salmonella typhimurium is one of several salmonella strains to have evolved in pigs. Furthermore, another very recently published government study found that 28% of British pigs tested positive for salmonella. 92% of these showed resistance to antibiotics with 67% being multiresistant. A British government survey in 2002 found that one in every twelve sausages (8.6%) were contaminated with salmonella.
Research has shown that pigs raised indoors excrete higher levels of salmonella in their manure than do outdoor-raised pigs, both organic and non-organic. Many scientific studies also show that salmonella in pigs increases with herd size.
Source and for more information: Soil Association
13 May 2011
Intervet/SP launches new atrophic rhinitis vaccine for pigs
//12 May 2011
Intervet/Schering-Plough Animal Health has introduced a new vaccine against progressive atrophic rhinitis in piglets.
The vaccine, called Porcilis AR-T DF, is an inactivated vaccine with a new adjuvant associated with fewer injection site reactions.
The vaccine uses Diluvac Forte (DF), an aqueous vitamin E-based adjuvant and it will replace Porcilis AR-T, a similar vaccine containing an oil-based adjuvant. The newly formulated vaccine is approved to reduce the clinical signs of progressive atrophic rhinitis in their offspring.
Atrophic rhinitis
Atrophic rhinitis is an inflammation of the nose mucosal tissue of both suckling and growing pigs. During the process of infection the delicate turbinate bones in the nose become damaged and may shrink or become distorted. There are two forms of the disease: mild and non-progressive where the infection or irritation occurs over a period of two to three weeks. The serious disease form is progressive atrophic rhinitis where toxin-producing strains of P. multocida present in the herd cause a continual and progressive inflammation and atrophy of the tissues.
The clinical characteristics are nose bleeds, shortening of the upper jaw and reductions of daily weight gain, resulting in significant economic losses for pig farmers.
Pasteurella and Bordetella
The new vaccine contains protein dO, a non-toxic gene deletion derivative of the P. multocida dermonecrotic toxin as well as inactivated Bordetella bronchiseptica bacterial cells. B. bronchiseptica is often present with P. multocida and is considered an important predisposing factor for the disease. When pregnant sows are vaccinated, their immune system starts to produce antibodies, which are then passed onto the piglets via colostrum to protect them against the disease.
Field trials with the novel vaccine have shown good protection against the clinical signs of progressive atrophic rhinitis in piglets. In a direct comparative study of the new vaccine against the previous version (without Diluvac Forte), colostrum of vaccinated sows had comparable levels of antibodies against progressive atrophic rhinitis, whereas there were significantly fewer tissue reactions at the injection site in the novel vaccine’s group.
In a placebo-controlled study, piglets from vaccinated sows were protected by the maternally derived antibodies against clinical signs of progressive atrophic rhinitis and had a higher average daily weight gain as well as higher carcass weight at slaughter as compared to untreated controls.
Related website:
• Intervet/Schering-Plough Animal Health
Intervet/Schering-Plough Animal Health has introduced a new vaccine against progressive atrophic rhinitis in piglets.
The vaccine, called Porcilis AR-T DF, is an inactivated vaccine with a new adjuvant associated with fewer injection site reactions.
The vaccine uses Diluvac Forte (DF), an aqueous vitamin E-based adjuvant and it will replace Porcilis AR-T, a similar vaccine containing an oil-based adjuvant. The newly formulated vaccine is approved to reduce the clinical signs of progressive atrophic rhinitis in their offspring.
Atrophic rhinitis
Atrophic rhinitis is an inflammation of the nose mucosal tissue of both suckling and growing pigs. During the process of infection the delicate turbinate bones in the nose become damaged and may shrink or become distorted. There are two forms of the disease: mild and non-progressive where the infection or irritation occurs over a period of two to three weeks. The serious disease form is progressive atrophic rhinitis where toxin-producing strains of P. multocida present in the herd cause a continual and progressive inflammation and atrophy of the tissues.
The clinical characteristics are nose bleeds, shortening of the upper jaw and reductions of daily weight gain, resulting in significant economic losses for pig farmers.
Pasteurella and Bordetella
The new vaccine contains protein dO, a non-toxic gene deletion derivative of the P. multocida dermonecrotic toxin as well as inactivated Bordetella bronchiseptica bacterial cells. B. bronchiseptica is often present with P. multocida and is considered an important predisposing factor for the disease. When pregnant sows are vaccinated, their immune system starts to produce antibodies, which are then passed onto the piglets via colostrum to protect them against the disease.
Field trials with the novel vaccine have shown good protection against the clinical signs of progressive atrophic rhinitis in piglets. In a direct comparative study of the new vaccine against the previous version (without Diluvac Forte), colostrum of vaccinated sows had comparable levels of antibodies against progressive atrophic rhinitis, whereas there were significantly fewer tissue reactions at the injection site in the novel vaccine’s group.
In a placebo-controlled study, piglets from vaccinated sows were protected by the maternally derived antibodies against clinical signs of progressive atrophic rhinitis and had a higher average daily weight gain as well as higher carcass weight at slaughter as compared to untreated controls.
Related website:
• Intervet/Schering-Plough Animal Health
04 May 2011
Ceva opens new poultry vaccine production facility
//04 May 2011
Ceva Animal Health is pleased to announce the May 3, 2011 opening of a new poultry vaccine production facility at its Biomune Campus in Lenexa, Kansas.
“After many years of building a strong research and development base, along with a fine sales force and excellent technical support, we are investing in our future growth with the opening of this new production facility,” said Dr. Arnaud Bourgeois, Vice President and Global Director of Biology at Ceva Santé Animale. “Increased demand for Ceva vaccines, plus the ability to create and utilize new vaccine technology not available from competitors made this the perfect time to build our new facility.”
Ceva Santé Animale purchased Lenexa-based Biomune Company in 2005, creating Ceva Animal Health as its US subsidiary. The purchase secured a strong foundation in research with Vectormune vaccines along with an aging manufacturing plant. With the opening of its new $18M facility, Ceva is poised to fill a global market need with high-quality vaccines. “Today, what we output is almost entirely for the domestic market,” explains Bourgeois, “ The new facility will double our domestic output while also allowing for expansion globally.” The existing plant will be renovated as part of Ceva’s long-term investment plan and is designated for a stand-alone custom vaccine project.
Ceva is well-known for its dedication to providing animal health products and services that ultimately benefit humans. The Biomune Campus’s contribution to the “One Health” effort is clear: poultry vaccines keep the world’s food supply safe and sufficient to meet the needs of an ever-growing population. “We continue to invest in our people and our facilities in order to innovate and therefore ensure that our products and services have a direct impact in improving global health,” said Marc Prikazsky, Chief Executive Officer of Ceva Santé Animale.
Ceva's new facility features:
· 55,000 square feet of innovative technology and automated systems
· State-of-the-art operations to ensure vaccine quality and consistent, safe supply
· Future physical plant growth/expansion opportunities
· Capability to product both standard and vector vaccines
· Career opportunities for 80 new production, research and development staff by 2015
Related website: CEVA
Ceva Animal Health is pleased to announce the May 3, 2011 opening of a new poultry vaccine production facility at its Biomune Campus in Lenexa, Kansas.
“After many years of building a strong research and development base, along with a fine sales force and excellent technical support, we are investing in our future growth with the opening of this new production facility,” said Dr. Arnaud Bourgeois, Vice President and Global Director of Biology at Ceva Santé Animale. “Increased demand for Ceva vaccines, plus the ability to create and utilize new vaccine technology not available from competitors made this the perfect time to build our new facility.”
Ceva Santé Animale purchased Lenexa-based Biomune Company in 2005, creating Ceva Animal Health as its US subsidiary. The purchase secured a strong foundation in research with Vectormune vaccines along with an aging manufacturing plant. With the opening of its new $18M facility, Ceva is poised to fill a global market need with high-quality vaccines. “Today, what we output is almost entirely for the domestic market,” explains Bourgeois, “ The new facility will double our domestic output while also allowing for expansion globally.” The existing plant will be renovated as part of Ceva’s long-term investment plan and is designated for a stand-alone custom vaccine project.
Ceva is well-known for its dedication to providing animal health products and services that ultimately benefit humans. The Biomune Campus’s contribution to the “One Health” effort is clear: poultry vaccines keep the world’s food supply safe and sufficient to meet the needs of an ever-growing population. “We continue to invest in our people and our facilities in order to innovate and therefore ensure that our products and services have a direct impact in improving global health,” said Marc Prikazsky, Chief Executive Officer of Ceva Santé Animale.
Ceva's new facility features:
· 55,000 square feet of innovative technology and automated systems
· State-of-the-art operations to ensure vaccine quality and consistent, safe supply
· Future physical plant growth/expansion opportunities
· Capability to product both standard and vector vaccines
· Career opportunities for 80 new production, research and development staff by 2015
Related website: CEVA
Subscribe to:
Posts (Atom)